- Category: HCV Treatment
- Published on Wednesday, 22 May 2013 00:00
Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after 3 months, according to findings from the PROMISE study presented at the Digestive Disease Week meeting (DDW 2013) this week in Orlando.
- Category: HCV Testing & Diagnosis
- Published on Wednesday, 15 May 2013 00:00
May 19 is the second annual Viral Hepatitis Testing Day, an opportunity to raise awareness among healthcare providers and the public about screening for chronic hepatitis B and C. According to the Centers for Disease Control and Prevention (CDC), an estimated 75% of people with hepatitis C virus (HCV) are not aware they are infected.
EASL 2013: ACH-3102 and Sovaprevir Show Potent Activity, High Barrier to Resistance in Early Studies
Achillion Pharmaceuticals' second-generation NS5A inhibitor ACH-3102 demonstrated potent activity against genotype 1a and 1b hepatitis C virus (HCV) and can be safely co-administered with the company's investigational protease inhibitor sovaprevir (formerly ACH-1625), according to studies presented at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
On May 13, Janssen announced that its application for approval of the next-generation hepatitis C virus NS3/4A protease inhibitor simeprevir (formerly TMC435) has received priority review status from the U.S. Food and Drug Administration (FDA), giving it an estimated timeline of 6 months.
A dual regimen of sofosbuvir (formerly GS-7977) plus ledipasvir (formerly GS-5885) for 8 or 12 weeks produced 4-week post-treatment sustained virological response (SVR4) rates of 95% to 100% for both treatment-naive and previously treated hepatitis C patients in a small Phase 2 study, according to a recent announcement from Gilead Sciences, developer of both drugs.
For people with chronic hepatitis C who cannot wait for all-oral regimens, interferon-based therapy is still a reality. Researchers at the recent EASL International Liver Congress (EASL 2013) presented promising data showing that several experimental direct-acting antiviral agents (DAAs) can significantly improve response rates without reducing tolerability.
EASL 2013: Triple Therapy for Hepatitis C Is Effective after Liver Transplantation but Comes with Side Effects
Adding the approved HCV protease inhibitor telaprevir (Incivek or Incivo) to pegylated interferon and ribavirin can increase sustained response rates even for difficult-to-treat liver transplant recipients, but adverse events are common, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
About half of patients taking boceprevir (Victrelis) or telaprevir (Incivek or Incivo) developed anemia and approximately one-third experienced skin rash, but sustained response rates were high in an analysis of a population representative of people with chronic hepatitis C in North America, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
- Category: HCV Treatment
- Published on Thursday, 09 May 2013 00:00
Widespread use of new direct-acting antiviral agents (DAAs) for hepatitis C could dramatically lower the rate of HCV transmission among people who inject drugs in 3 hard-hit cities, according to a math model described in the March 28, 2013, issue of Hepatology.
They assumed that interferon-free regimens would produce 90% sustained virological response (SVR) with 12 weeks of treatment and would be available by 2015 -- all "realistic scenarios" based on the latest research.
- HCV Treatment
- HCV Prevention
- HCV Testing & Diagnosis
- HCV Disease Progression
- HCV-Related Conditions
- Side Effects - HCV
- HCV Basic Science
- HCV Epidemiology & Mortality
- HCV Populations
- HCV Policy & Advocacy
- HCV Resources